Is radiation exposure during sacral neuromodulation within safety limits?

Ali Alabbad, MD¹; Elie Abdo, MD²; Magdy Hassouna, MD²

¹King Fahad Specialist Hospital, Dammam, Saudi Arabia; ²University of Toronto, Toronto, ON, Canada

Introduction

The U.S. Food and Drug Administration (FDA) approved sacral neuromodulation (SNM) for intractable urge incontinence in 1997, urgency/frequency syndrome and non-obstructive urinary retention in 1999 for patients who failed to respond or could not tolerate conservative treatment.¹ In 2011, the FDA approved SNM for chronic fecal incontinence in patients who failed or could not tolerate conservative treatment.

Fluoroscopy guidance is recommended during permanent tined lead insertion in the S3 foramen. Before InterStim® system implantation, the patient underwent a clinical trial either by basic evaluation using temporary lead in the S3 foramen, (also referred to as peripheral nerve evaluation [PNE]), which is a simple, in-office procedure for external stimulation, or by advanced evaluation using permanent tined lead in the S3 foramen under fluoroscopy guidance (also referred to as stage I), which is initiated through an outpatient procedure performed in a hospital or surgical centre for external stimulation. Both evaluations are short-term and the effects are reversible by removing the leads or turning off the device. Stage II is implantation of a subcutaneous implantable pulse generator (IPG). If PNE was performed, fluoroscopic confirmation for the new permanent tined electrode placed in the S3 foramen is advised, followed by the implantation of a subcutaneous IPG in the same sitting. Fluoroscopy uses X-rays, which can cause cellular damage and even cell death. The amount of damage depends on the total dose, duration of exposure, and site of exposure. This damage can lead to biological effects, which may be stochastic (independent of the dosage received) or deterministic (dose-dependent effects).²³ The major source of radiation is the C-arm, which is used to produce images for surgical guidance. The radiation exposure can be direct or indirect. Direct exposure is when the person is in the line of the radiation rays produced by the fluoroscopy machine. Indirect exposure occurs from scattered rays resulting from the interaction between the primary beam and the patient, which disseminate in all directions.³⁴

The guidelines approved in 2009 by the Society of Interventional Radiology (SIR) and Cardiovascular & Interventional Radiology Society of Europe (CIRSE) identify patients with potential skin injuries requiring clinical followup: peak skin dose >3 Gy, air kerma at the patient entrance reference point >5 Gy, kerma area product >500 Gy·cm², or fluoroscopy time >60 minutes.⁵

Methods

The medical charts of patients who underwent InterStim implantation performed by one surgeon and his trained fellows or residents between January 2014 and July 2016 were reviewed retrospectively. Approval was obtained from the Research Ethic Board of University Health Network (#16-5889-AE). Patients’ demographic data, body mass index (BMI), indication of treatment, radiation dose data (fluoroscopy time [FT], cumulative dose (CD), which is also known as air kerma at the patient entrance reference point (usually measured in mGy), dose area product (DAP), which also known as kerma area product (usually measured in Gy·cm²), the nature of the surgery, and operation time were collected. The results were compared to radiation exposure during ureteroscopy (FT 44 sec; DAP 6.01 Gy·cm²; CD 12 mGy).⁶⁻⁸

Results

A total of 141 medical charts were reviewed; 83 patients were included in our study and 58 patients were excluded due to insufficient radiation dose data. The fluoroscopy machine used during tined lead insertion was the General Electric OEC 9900 Elite. The majority of subjects were females (67.5%), mean age was 58.3 years (range 21–86, standard deviation [SD] 14), and mean BMI was 28.9 kg/
The indications of the treatments were as follows: overactive bladder syndrome (50.6%), idiopathic urinary retention (36.2%), painful bladder syndrome (7.2%), fecal incontinence (4.8%), and nocturnal enuresis (1.2%). Full implantation was the most common surgery (47%), followed by stage implantation (34.9%), revision (17%), and twin implantation (1.2%). The mean operation time was 37.16 minutes (21–69, SD 10). The FT was measured in 83 patients; the mean FT was 31.03 seconds (9.5–155, SD 20). The CD was measured in 50 patients; the mean CD was 13.36 mGy (2.11–33.11, SD 4). Thus, radiation exposure during InterStim implantation is comparable to radiation exposure during ureteroscopy and based on the guidelines approved in 2009 by the SIR and CIRSE, which identify patients with potential skin injuries requiring clinical followup, the FT, CD and DAP during interStim implantation were well within the threshold level for radiation exposure (peak skin dose >3 Gy, air kerma at the patient entrance reference point >5 Gy, kerma area product >500 Gy·cm², or fluoroscopy time >60 minutes).

Discussion

The International Commission on Radiation Protection (ICRP) recommends guidelines for radiation exposure. For medical personnel, it has been recommended that the exposure should not exceed 20 mSv per year. The maximum duration for which this level of exposure is allowed is five years, hence a maximal total body exposure over five years should not exceed 100 mSv. “Radiation exposure is minimal during sacral neuromodulation, the cumulative dose for physicians should not be ignored. With a mean exposure of 1.7 mrem during an initial lead placement, a physician is exposed to the equivalent of one chest X-ray with every 4.7 procedures.”

We are aware of the limitations in our study, as it is a retrospective in nature with a small sample size.

Conclusion

The level of radiation exposure patients encounter during InterStim implantation is minimal and comparable to the level of radiation exposure patients encounter during ureteroscopy.

Competing interests: The authors report no competing personal or financial interest related to this work.

Acknowledgement: This abstract was previously presented at the 2017 International Continence Society meeting, Sept.12–15, 2017, Florence, Italy.

This paper has been peer-reviewed.

References

1. Shaker HS, Hassouna M. Sacral root neuromodulation in idiopathic non-obstructive chronic urinary retention. J Urol 1998;159:1476-8. https://doi.org/10.1097/00005392-199805000-00017
2. Jindal T. The risk of radiation exposure to assisting staff in urological procedures: A literature review. Urol Nurs 2013;32:136-9. https://doi.org/10.7257/1053-816X.2013.32.136
3. Rehani MM, Ciraj-Bjelac O, Vano E, et al. Radiological protection in fluoroscopically guided procedures performed outside the imaging department. Ann ICRP 2010;40:1-102. https://doi.org/10.1016/j.icrp.2012.03.001
4. Kumari G, Kumar P, Wadhwa P, et al. Radiation exposure to the patient and operating room personnel during percutaneous nephrolithotomy. Int Urol Nephrol 2006;38:207-10. https://doi.org/10.1007/s11255-005-4972-9
5. Vano E, Fernandez JM, Sanchez RM, et al. Patient radiation dose management in the followup of potential skin injuries in neuroradiology. Am J Neuroradiol 2013;34:277-82. https://doi.org/10.3174/ajnr.A3211
6. Hadjipavlou M, Lam V, Seth J, et al. Predicting radiation exposure in ureterorenoscopy and laser lithotripsy: An analysis of patient and stone characteristics. J Urol 2015;193:ax317. https://doi.org/10.1016/j.juro.2015.02.1241
7. Prisco C, Maier A, Negru D, et al. Extracorporeal shock waves lithotripsy vs. retrograde ureteroscopy: Is radiation exposure a criterion when we choose which modern treatment to apply for ureteric stones? BMJ Basic Med Sci 2014;14:254-8. https://doi.org/10.17305/ajfms.2014.4.99
8. Hristova-Popova J, Salimov I, Pelikova K, et al. Radiation exposure to staff and patients during two endourological procedures. European Medical Physics and Engineering Conference, Sofia 2012.
9. Murphy A, Lee C, Wunderle K, et al. Radiation exposure to the patient and physician during sacral neuromodulation. J Urol 2012;187:e549. https://doi.org/10.1016/j.juro.2012.02.1737

Correspondence: Dr. Ali Alabbad, King Fahad Specialist Hospital, Dammam, Saudi Arabia; Ali.bbad@kfsh.med.sa